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Abstract: The report of an increased frequency of melanoma
during the clinical development of rasagiline prompted a
renewed interest in a possible association between skin cancer
and Parkinson’s disease (PD). The evaluation of this risk ended
in a recommendation to perform a periodic dermatological ex-
amination as a follow-up measure of their treatment. The rec-
ognition of this safety concern lead to the need to clarify if the
risk of skin cancer is indeed associated with PD and if levo-
dopa or other anti-parkinsonian drugs might contribute to
increase such risk. To answer these questions, we critically
reviewed all clinical studies available concerning the associa-
tion between skin cancer and PD. We found 26 studies on can-
cer occurrence in PD. The best data available suggest the risk
of cancer is reduced in PD patients. However, specific cancers
like thyroid and the female breast were reported at higher-than-
expected rates. Additionally, it was suggested that PD patients
have a higher frequency of melanoma and non-melanoma skin
cancers than the general population. The data on non-mela-
noma skin cancer are less robust than the data on melanoma.
Causal factors remain unknown. Due to the weak association
between skin cancer and PD, no robust recommendation can be
made regarding the need for periodic dermatological screen-
ing.  2010 Movement Disorder Society
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Concern about an increased risk of skin cancer in
Parkinson’s disease (PD) patients was first raised by
Skibba (1972) based upon a case of recurrent malig-
nant melanoma in a PD patient treated with levodopa
(L-dopa).1 Since then, more than 50 cases of newly
diagnosed melanoma, melanoma recurrence, or mela-
noma metastasis were reported in L-dopa-treated PD
patients.2
These case reports were sufficient to raise safety
concerns to an extent that, since 1976, a formal contra-
indication exists for the use of L-dopa in PD patients
with melanoma. For example, Sinemet and Madopar
yield the warning ‘‘(. . .) because levodopa may acti-
vate a malignant melanoma, it should not be used in
patients with suspicious, undiagnosed skin lesions or a
history of melanoma.’’3 The association between levo-
dopa therapy and melanoma was considered theoreti-
cally plausible because L-dopa is a substrate for the
synthesis of dopamine and melanin.4–6
The finding of an increased frequency of melanomas
during the clinical development of rasagiline prompted
a renewed interest in a possible association of skin
cancer and PD. The evaluation of this risk ended in a
recommendation to perform periodic dermatological
examinations in patients as follow-up measure of their
treatment.7–9 A similar amendment was later added to
the safety labels of pramipexole,10 ropinirole,11 and
selegiline.12
To review the association between skin cancers and
PD, we critically analyzed the epidemiological and
clinical studies available. First, we reviewed data on
the global risk of cancer in PD. As a second step, we
focused on specific studies evaluating the risk of mela-
noma and other skin cancers in PD patients.
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SEARCH STRATEGY AND
SELECTION CRITERIA
We searched the database Medline (1966–2008)
with the terms ‘‘cancer,’’ ‘‘mortality,’’ ‘‘melanoma,’’
and ‘‘Parkinson’s disease’’. We also searched refer-
enced lists of identified studies on cancer and mela-
noma in PD and handsearched the abstract books of
international congresses of movement disorders. All
studies aimed at evaluating the frequency of any type
of cancer or cancer related mortality in PD were
selected.
Quality of published methodology data and related
susceptibility to bias were assessed through a check-
list approach for study design, diagnostic criteria of
PD, type of cancer ascertainment, and statistical
analysis.
STUDIES ABOUT CANCER RISK IN PD
The first comment about cancer in PD was made by
Doshay in 1954 who concluded from the analysis of a
case series that cancer was rare in ‘‘paralysis agi-
tans.’’13 Several other studies followed from other case
series, chart reviews, prospective cohorts, or case-con-
trol studies. In Table 1, we present all known studies
for which the primary or secondary objectives were to
evaluate the frequency of cancer in PD patients.
Hoehn and Yahr investigated the cause of death in
194 patients with PD and found that 24 patients had
died of malignant neoplasms.16 When compared with
the expected number calculated using the New York
population as reference (41 cases), they concluded that
a lower rate of death by malignant neoplasm occurred
in PD patients (P < 0.001).16 Interestingly, 5 cases of
skin cancers from 69 cases of malignant neoplasms
were reported. There was no description of the type of
skin lesion and no comparison was made with the
expected prevalence of skin cancers in the reference
population.
Jansson and Jankovic19 retrospectively reviewed 406
medical charts of PD patients and identified 18 patients
with cancer, when compared with an expected number
of 41.9. The exception to these lower cancer rates were
malignant melanoma (2 cases observed vs. 0.3 expected,
P 5 0.04) and thyroid tumors (3 cases, all in women,
P < 0.001). Interestingly, non-melanoma skin cancers
occurred less frequently than expected (10 cases
observed vs. 49.9 expected, P < 0.0001). The L-dopa
dose, duration of treatment, and other risk factors related
to the disease were not included in the analysis. The
authors concluded that the rate of cancer and non-mela-
noma cases was low, but the number of cases of malig-
nant melanoma was higher than expected.
Elbaz et al.27 conducted a population-based case-
control study to investigate the association of PD with
nonfatal cancer. They used the medical records-linkage
system of the Rochester Epidemiology Project (1976–
1995). Each case was matched by age and sex to a
general population control. The frequency of cancer in
general was lower in PD cases (19.4%) than in controls
(23.5%) (OR 0.79; 95% CI 0.49–1.27). This pattern
was more pronounced in women than in men and in
patients aged 71 years or younger at onset of PD. They
did not find an association between PD and nonfatal
cancer. However, they did find a decreased prevalence
of smoking-related cancers and an increased prevalence
of malignant melanoma. This latter finding was based
on 3 observed cases in the patient group.
The same authors28 used the same approach to
investigate the risk of cancer after the diagnosis of PD.
They included 196 patients and 185 control subjects in
this study. The risk of cancer was higher among
patients than in controls (RR 1.64; 95% CI 1.15–2.35;
P 5 0.007). The increased risk was significant for
non-melanoma skin cancers (RR 1.76; 95% CI 1.07–
2.89; P 5 0.03). Among PD patients, there was no
relation between the risk of cancer and the cumulative
dose of L-dopa or the use of other PD medications. No
other types of cancer were found to be associated with
PD. However, these analyses were hampered by the
small sample size and a potential surveillance bias.
Moller et al.22 conducted a retrospective study in a
cohort of 7,046 patients with a primary diagnosis of
PD obtained from a Danish hospital discharge compu-
terised register (during 1977–89). Information on can-
cer incidence and death among cohort members from
their first recorded admission for PD until the end of
1990 was obtained from the Danish cancer registry
and from the Danish registry of deaths (the average
duration of follow-up was 4.6 years). The Danish Can-
cer Registry began reporting incidence data in 1943
and includes cases of non-melanoma skin cancers (ba-
sal cell and squamous cell carcinoma). The expected
numbers of cancer cases were calculated from the per-
son’s years at risk among cohort members and the
incidences of cancer in the Danish population. The
overall incidence of cancer was lower than expected
(relative risk 0.88, 95% CI 0.8–1.0). However, a sig-
nificant increase in relative risk was seen for skin mel-
anoma (relative risk 1.96, 95% CI 1.1–3.2). Relative
risks of other skin cancers also increased, although
this was not statistically significant (relative risk 1.24,
95% CI 1.0–1.5).
140 J. FERREIRA ET AL.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































An update of the Moller study22 was recently pub-
lished, covering a longer period (1977–98).30 Among
14,088 patients with a primary diagnosis of PD (aver-
age duration of follow-up of 5 years), 1,282 cancer
cases were subsequently recorded compared to 1,464
expected cases, with a standardized incidence ratio
(SIR) of 0.88 (95% CI 0.8–1.0), that is equivalent to a
12% reduction in the risk of cancer. Significantly
reduced risks were found for smoking-related cancers
(e.g. lung (SIR, 0.38), larynx (SIR, 0.47), and urinary
bladder (SIR, 0.52)) cancers. In contrast, increased
risks were seen for malignant melanoma (SIR, 1.95;
95% CI 1.4–2.6), non-melanoma skin cancer (1.25;
95% CI 1.1–1.4), and breast cancer (1.24; 95% CI 1.0–
1.5). The association between PD and melanoma was
higher in the 1st year after PD diagnosis and decreased
in subsequent periods. As in the first study, there was
also an increased relative risk for non-melanoma skin
cancers, which reached statistical significance in the
larger study. In both studies, there was no information
on treatment and the suspected role of L-dopa as a risk
factor for malignant melanoma could not be
investigated.
Driver et al.31 conducted a nested case-control study
within a prospective cohort of 22,071 US male physi-
cians to estimate the association between the diagnosis
of PD and the development of cancer. During the 22
years of follow-up, 487 cases of PD were identified
and age-matched to 487 controls. The frequency of
any cancer was lower in PD cases (13.1%) than in con-
trols (14.8%). The same research group conducted
another case-control study using the same cohort to
evaluate cancer incidence following the diagnosis of
PD. A total of 487 cases of PD without cancer were
age-matched to reference participants who were alive
and cancer-free at the time of PD diagnosis. A total of
121 cases of cancer were confirmed during a median
follow-up of 5.2 years (PD) and 5.9 years (reference).
Those with PD developed less cancer (11.0 versus
14.0%), with an adjusted RR of 0.85 [95% CI, 0.59–
1.22]. Reduced risk was present for smoking-related
cancers such as lung (RR, 0.32), colorectal (RR, 0.54),
and bladder (RR, 0.68), as well as for most non-smok-
ing-related cancers such as prostate cancer (RR, 0.74).
In contrast, PD patients were at a significantly
increased risk for melanoma (RR, 6.15; 95% CI, 1.77–
21.37).32
The most robust evidence concerning the global risk
of cancer in PD derives from the results of the Danish
PD cohort studies.22,30 All other epidemiological stud-
ies have small samples and inadequate statistical power
to conclusively assess the risk for skin cancer (mela-
noma and non-melanoma) with reasonable precision.
Overall, data available are consistent and sufficiently
robust to conclude that PD is associated with a
decreased risk for cancer when compared with the gen-
eral population. However, some cancer types have
been reported to occur in excess of expected numbers
including malignant melanoma of the skin, other skin
cancers, and cancers of the thyroid and the female
breast.
STUDIES ON SKIN CANCER RISK IN PD
Recently, specific studies have investigated the prob-
lem of melanoma or other skin cancers in PD (Table
2). Different approaches were used to investigate the
potential association: determination of the frequency of
melanoma in PD patients’ cohorts; to investigate the
frequency of PD diagnosis in patients with a clinical
history of melanoma; to investigate risk factors for the
development of skin cancers in PD patients (e.g., L-
dopa treatment, other anti-parkinsonian treatments, or
other risk factors).
FREQUENCY OF MELANOMA IN
PD PATIENTS
Olsen and coworkers33 conducted a population-based
case–control study to investigate the prevalence of ma-
lignant melanoma, skin carcinoma, and other cancers
before a first hospitalization or outpatient visit for PD.
They identified 8,090 patients with a primary diagnosis
of PD during the period of 1986–1998 from the
National Danish Hospital Register. Each case was
matched with four population controls selected at ran-
dom from among inhabitants alive at the date of first
hospital contact with the patient. The number of cancer
cases since 1943 were obtained from the Danish Can-
cer Registry. The study found an increased prevalence
of malignant melanoma and skin carcinoma before the
first hospital contact for PD, with overall odds ratios of
1.44 (95% CI 1.03–2.01) and 1.26 (95% CI 1.11–
1.43), respectively. Cancers showed a reduced preva-
lence at smoking-related sites.
A cross-sectional survey to assess the frequency and
characteristics of skin neoplasms in PD patients was
conducted in 12 medical centres in Israel.34 Of the
1,395 patients included, 9 patients (0.6%) had a histo-
logically confirmed diagnosis of malignant melanoma
(1 invasive; 8 in situ), 14 patients (1.0%) had mela-
noma in their medical history, and 6 patients had mela-
noma diagnoses before and 8 after their PD diagnosis.
The total number of patients with current or prior mel-
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anoma was 20 (1.4%). Occurrence of melanoma did
not correlate with PD duration, H&Y stage, or L-dopa
treatment. Analysis of prevalence data (5-year limited
duration) for a comparable time period from the Israel
National Cancer Registry suggested an overall relative
rate of melanoma of 4.4 (95% CI 2.6–7.6) times
greater than expected based on an age- and sex-
matched population.34
Bertoni et al.35 performed another cross-sectional
survey in 2,106 North American PD patients who
underwent a full-body dermatological examination and
biopsy of any suspicious skin lesions. Of the 346
patients with suspicious pigmented lesions, 20 had his-
thologically confirmed in situ melanomas (0.95%) and
4 had invasive melanomas (0.19%). No relationship
between the occurrence of melanoma (before or at ex-
amination) and L-dopa usage was observed. Prevalence
(5-year limited-duration) of invasive melanoma in US
PD patients (n 5 1,692) was 2.2-fold higher (95% CI
1.21–4.17) than expected in age- and sex-matched pop-
ulations in the National Surveillance Epidemiology and
End Results—US Cancer Statistics Review database
(SEER). Compared with American Academy of Der-
matology screening programs, age- or sex-adjusted rel-
ative risk of any melanoma at screening was more than
eight times higher for US patients.
A small cross-sectional survey found more neoplastic
or pre-neoplastic lesions in PD patients (23.3%) when
compared to age matched controls (13.7%) (OR 95%CI
1.92 [1.05, 3.51]). 36 Likewise, more cases of actinic ker-
atosis (19%) and basal cell carcinoma (3%) were diag-
nosed in PD patients, suggesting that pre-neoplastic skin
lesions, such as actinic keratosis, could also play a role in
the increased risk of PD patients to develop melanoma.
Constantinescu et al.37 evaluated the frequency of ma-
lignant melanoma in the DATATOP clinical trial cohort.
The DATATOP cohort included 800 patients enrolled
between September 1987 and November 1988, and fol-
lowed until 1994. Five cases of melanoma were found
when compared with an expected number of 1.5 after
adjusting for age and gender (standardized event ratio 3.3
[95% CI 1.1–7.8]). Two cases of malignant melanoma
were diagnosed before the L-dopa treatment onset, and 3
cases occurred after 1, 6, and 19 months. No conclusion
could be made about an association between L-dopa ther-
apy and the incidence of melanoma.
FREQUENCY OF PD IN MELANOMA
PATIENTS
Rigel et al.38 performed a case-controlled study in
862 malignant melanoma patients and 862 controls
with no history of melanoma or pigmented lesion-
related problems. Cases and controls were matched by
age and gender. Cases of malignant melanoma were
collected from US academic dermatology clinics.
Among the melanoma patients, 25 (2.9%) cases had
PD compared with 11 (1.3%) controls with PD. The
authors concluded that the odds of having PD was
more than twofold greater in patients with malignant
melanoma than in the control subjects.
Baade et al.39 conducted a cohort study of all patients
diagnosed as having melanoma in Australia since 1982
(n 5 127,037). The subjects were followed through the
end of 2001. Their cohort had a risk of death due to
amyotrophic lateral sclerosis (ALS) that was 70% higher
(standardized mortality ratio 5 169.4, 95% CI 5 127–
221) than the general population, and nearly a threefold
increased risk of dying from PD (standardized mortality
ratio 5 266.3, 95% CI 5 222–317). These increased
risks continued for long-term survivors, arguing against
a surveillance effect (particularly for ALS).
LEVODOPA AS A RISK FACTOR
FOR MELANOMA
Since the early 1970s, a number of case reports have
suggested that L-dopa therapy increased the risk of cu-
taneous malignant melanoma. However, this safety
concern was based on a limited number of anecdotal
reports, and on cases where melanoma preceded L-
dopa treatment, in which a formal causal-relationship
evaluation would preclude such a link. There are also
cases with no exacerbation or recurrence of melanoma
in patients that were kept on L-dopa therapy. The data
from these case reports are also limited in terms of
patient characteristics that could be correlated with an
increased risk for melanoma, such as sun exposure,
family history, or fair skin.
The only epidemiological study that has specifically
evaluated the role of L-dopa was conducted by Sober
et al.40 They conducted a prospective survey in 1,099
patients from the Melanoma Clinical Cooperative
Group. At the time of presentation of their primary mel-
anoma, only 1 patient had been taking L-dopa. The
authors concluded that L-dopa had no role in the induc-
tion of melanoma. No other formal epidemiological
study has been conducted to test the hypothesis that L-
dopa therapy for PD increases the risk of cutaneous ma-
lignant melanoma. Interestingly, the hypothesis that L-
dopa could be toxic to the melanocytes was raised in the
1970s.41 Although its efficacy was never demonstrated,
high doses of oral L-dopa were used in practice to treat
metastatic malignant melanomas.42
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OTHER ANTI-PARKINSONIAN DRUGS AND
SKIN CANCER
There are no epidemiological studies evaluating the
frequency of skin cancer in PD patients treated with
any anti-Parkinsonian drug other than L-dopa. All data
available are derived from adverse events reported in
published clinical trials or registered in pharmacovigi-
lance systems.43,44
DISCUSSION
From this analysis of all the data available regarding
the association between PD and skin cancer, melanoma
occurs at a higher frequency in PD patients when com-
pared with the general population. Similarly, although
not so robustly demonstrated, non-melanoma skin can-
cers appear at an increased frequency in PD patients.
The studies available were not designed to enable con-
clusions to be made regarding the causal relationship
between L-dopa and skin cancers.
Due to the heterogeneity of study designs and out-
come measures, no statistical pooling of the results
was appropriate to be conducted. Nevertheless, a de-
scriptive analysis of the best data suggest a prevalence
of melanoma in PD patients between 1.1 and 1.4 %
and a 1.5–3-fold increase in the incidence of mela-
noma. If we apply these estimates to the expected inci-
dence of melanoma in the United States for subjects
65–years-old and older (65.4 per 100.000 per year;
SEER 2001–2005), we presume an approximate inci-
dence of 1 to 2 cases per 1000 PD patients per year
(slight increased risk).
The theory linking L-dopa and melanoma was based
on the shared biochemical pathways between the syn-
thesis of both dopamine and melanin. The association
between L-dopa and melanoma is therefore based on
biological plausibility and a few case reports where
data is too limited to determine the causality.1,45–47 In
some cases, the short interval between the onset of L-
dopa treatment and the diagnosis of melanoma makes
it somewhat implausible that a carcinogenic effect is
induced by L-dopa. On the other hand, the reported
stronger association between PD and melanoma within
the first years after PD diagnosis30 reduces the likeli-
hood that these cases of melanoma are due to PD treat-
ment and suggests the possibility of other pre-existing
causal or confounding, unknown factors.
Additionally, the association of PD with non-mela-
noma skin cancers counters the theory of L-dopa as a
causal factor, unless the biochemical pathway includ-
ing L-dopa is common to all types of skin cancer. As
one of the common causative factor is long-term sun
exposure,48,49 it may be hypothesized that PD patients
are more sensitive to sun-exposure-induced skin
lesions. This may be due to a disease-specific suscepti-
bility or to a photocarcinogenic potential of L-dopa or
other anti-parkinsonian drugs. The increased rate of
malignant melanoma and non-melanoma skin cancers
before the diagnosis of PD weakens the hypothesis that
skin cancers may be caused by the treatment of PD.33
Furthermore, although exogenous L-dopa was sug-
gested to have some effect on melanin synthesis, con-
sequently, stimulating melanogenesis and melanoma
growth,50 it has not been demonstrated that L-dopa is
carcinogenic. Other theories for L-dopa-induced mela-
noma included inhibition of the pineal gland,51
increased plasma concentrations of growth hormone,52
and mediation of immunosuppression by enhancing
secretion of melanocyte-stimulating hormone.51 Inter-
estingly, L-dopa and other precursors in the biosyn-
thetic pathway of melanin may have a toxic effect on
melanoma in vitro.53 The two clinical surveys specifi-
cally conducted to evaluate the frequency of cutaneous
lesions in PD patients concluded that an extremely
high prevalence of melanoma existed (1.4% in Israel
and 1.1% in North America). However, the interpreta-
tion of these rates is difficult without a parallel control
group or a valid external database. This is even more
difficult knowing both that the incidence of melanoma
has sharply increased in the last 70 years,54 and that
the overall calculation of melanoma incidence in the
general population is imprecise because rate figures are
calculated based on data collection systems that cannot
find cases of less-invasive disease.
The incidence of PD increases with age and the inci-
dence of malignant melanoma has been increasing in
recent decades. Consequently, it is expected that both
PD and malignant melanoma will coincidentally affect
several patients every year, even without a causal rela-
tionship between the two diseases. On the other hand,
if the increased risk in PD patients is caused by envi-
ronmental or genetic factors common to both diseases,
it would be expected that the association between PD
and skin cancer be bidirectional (i.e., that the risk for
malignant melanoma would also be increased before a
diagnosis of PD) that cannot be excluded with the data
available. In the scenario of an independent common
cause for PD and melanoma, we would expect either
to have melanoma first and PD after or vice-versa.
Nevertheless, given that cancer has a much higher
mortality it might happen that there is no time to de-
velop PD once cancer occurs. In this situation, it would
result that it should be more frequent to identify PD
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cases were cancer was found after the neurological di-
agnosis, than the inverse.
So far all the melanoma reports refer to cutaneous
melanoma, with no data regarding the occurrence of
ocular melanoma. This may be because of its rarity or
be justified by its being more difficult to screen in pri-
mary dermatologic surveys.
In summary, from the data available, there is:
1. Consistent data supporting an association between
cutaneous melanoma and PD;
2. A possible association between non-melanoma skin
cancers and PD;
3. Insufficient data to conclude on the association
between L-dopa and melanoma in PD patients;
4. Insufficient data to conclude on the association
between rasagiline, selegiline, ropinirole, pramipex-
ole or other anti-parkinsonian drugs and melanoma
or other skin cancers in PD patients;
5. Insufficient data about the risk factors for skin can-
cer in PD patients.
IMPLICATIONS FOR PRACTICE
Physicians and PD patients should be made aware of
the association between PD and skin cancers.
No robust recommendation can be made regarding
the need for periodic dermatological screening.
IMPLICATIONS FOR RESEARCH
In our opinion, there is a clear need to understand the
risk factors for the association between melanoma and
other non-melanoma cancers and PD. To investigate the
putative role of medications requires a prospective, case-
control study designed to examine the main risk factors
for the development of skin cancers in PD patients. This
study should be a large study focused on patients with
more than 5 years of disease treatment and without any
restriction in terms of anti-parkinsonian drugs. It will be
crucial to have parallel prospective controls using the
same case-ascertainment methods.
Any clinical survey or pharmacoepidemiological
study about this safety problem should also include a
balanced effort to identify not only melanoma but also
all neoplastic and pre-neoplastic skin lesions.
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